- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-377/18: Judgment of the General Court of 28 June 2019 — Intercept Pharma and Intercept Pharmaceuticals v EMA (Access to documents — Regulation (EC) No 1049/2001 — Documents held by EMA containing information submitted by the applicants in the context of the marketing authorisation for the medicinal product Ocaliva — Decision to grant a third party access to a document — Exception relating to the protection of court proceedings)
ECLI:EU:UNKNOWN:62018TA0377
62018TA0377
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
26.8.2019
Official Journal of the European Union
C 288/51
(Case T-377/18) (*)
(Access to documents - Regulation (EC) No 1049/2001 - Documents held by EMA containing information submitted by the applicants in the context of the marketing authorisation for the medicinal product Ocaliva - Decision to grant a third party access to a document - Exception relating to the protection of court proceedings)
(2019/C 288/64)
Language of the case: English
Parties
Applicants: Intercept Pharma Ltd (Bristol, United Kingdom) and Intercept Pharmaceuticals, Inc., (New York, New York, United States), (represented by: L. Tsang, J. Mulryne, E. Amos and H. Kerr-Peterson, Solicitors, and F. Campbell, Barrister)
Defendant: European Medicines Agency (represented by: initially by S. Marino, S. Drosos, A. Rusanov and T. Jabłoński, and subsequently by S. Marino, S. Drosos, T. Jabłoński, R. Pita and G. Gavriilidou, Agents)
Re:
Action under Article 263 TFEU for the annulment of EMA decision ASK-40399 of 15 May 2018, granting to a third party, pursuant to Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43), access to a document containing information submitted in the context of an application for marketing authorisation for the medicinal product Ocaliva.
Operative part of the judgment
The Court:
1.Dismisses the action;
2.Orders Intercept Pharma Ltd and Intercept Pharmaceuticals, Inc. to pay the costs.
(*)
Language of the case: English.
ECLI:EU:C:2019:140